The United States has announced plans to introduce Gilead Sciences’ breakthrough HIV prevention drug, lenacapavir, in Uganda starting in 2026 under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). Uganda is one of just ten high-burden HIV countries selected for the life-saving initiative.
Taken only twice a year, lenacapavir offers a highly effective and convenient HIV prevention option. Clinical trials indicate that more than 99% of people who used the drug remained HIV-negative. Officials say this innovation has the potential to save hundreds of thousands of lives worldwide.
The rollout will be implemented in partnership with the Ugandan Ministry of Health. Particular emphasis will be placed on vulnerable groups, including pregnant and breastfeeding mothers.
Ambassador William W. Popp hailed the drug as transformative, noting that it is a product of collaboration between U.S. researchers and Ugandan scientists.
“This medicine is an excellent example of how American leadership drives innovation to save lives. Collaboration between an American company and researchers right here in Uganda led to a medical breakthrough to reduce new HIV infections in the communities that need it most,” he said.
The U.S. government, together with the Global Fund—of which the United States is the largest donor—has committed to purchasing lenacapavir for up to 2 million people across the hardest-hit countries by 2028. Gilead has agreed to supply the drug at cost and share its intellectual property with generic manufacturers, ensuring broader access and long-term affordability.
Health experts say the drug could mark a turning point in Uganda’s decades-long fight against HIV/AIDS. With U.S. support, the Government of Uganda will now develop a nationwide rollout plan to ensure those most at risk benefit from this life-saving innovation.
